Thomas Farrington - Perrigo Company Senior Vice President CIO

PRGO -- USA Stock  

USD 55.72  0.98  1.73%

Mr. Thomas M. Farrington is Executive Vice President, Chief Information Officer of the Company. He formerly served as Senior Vice President and Chief Information Officer from October 2006 to November 2015.
Age: 60  President Since 2015      
353 1 709 4000

Management Efficiency

The company has return on total asset (ROA) of 2.34 % which means that it generated profit of $2.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 1.49 % meaning that it created $1.49 on every $100 dollars invested by stockholders.
The company currently holds 3.62B in liabilities with Debt to Equity (D/E) ratio of 63.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 1.88 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Ganadhish KamatDr Reddys Laboratories Ltd
Stefan WeiskopfZoetis
J RamachandranDr Reddys Laboratories Ltd
Catherine KnuppZoetis
Saumen ChakrabortyDr Reddys Laboratories Ltd
Roman TrawickiZoetis
Raghav ChariDr Reddys Laboratories Ltd
Ian SmithVertex Pharmaceuticals Incorpor
Christopher FenimoreRegeneron Pharmaceuticals
K RaoDr Reddys Laboratories Ltd
Umang VohraDr Reddys Laboratories Ltd
Roxanne LaganoZoetis
Marion McCourtRegeneron Pharmaceuticals
Alok SonigDr Reddys Laboratories Ltd
Heidi ChenZoetis
Michael AbermanRegeneron Pharmaceuticals
Michael PariniVertex Pharmaceuticals Incorpor
Sandra BeatyZoetis
George YancopoulosRegeneron Pharmaceuticals
Peter PowchikRegeneron Pharmaceuticals
Joseph LaRosaRegeneron Pharmaceuticals

Entity Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 20 shares of
a day ago
Traded for 15.09
Purchased few shares of
a day ago
Traded for 42.34
Purchased few shares of
a day ago
Traded for 119.16
Purchased over 100 shares of
a day ago
Traded for 2.27
Purchased one share of
a day ago
Traded for 274.08
Additionally take a look at Your Equity Center. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.